

Time of three months with a check in the amount of \$950.00.

In addition, the following references are submitted herewith as Exhibits 1-5, respectively: Elliott, M. J. et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor  $\alpha$ ," *Arthritis & Rheumatism*, 36(12):1681-1690 (1993); Elliott, M. J. et al., "TNF $\alpha$  Blockade in Rheumatoid Arthritis: Rationale, Clinical Outcomes and Mechanisms of Action," *Immunopharmac.*, 17(2):141-145 (1995); Maini, R. N. et al., "Monoclonal Anti-TNF $\alpha$  Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease," *Immunological Reviews*, No. 144:195-223 (1995); Kingsley, G. et al., "Immunotherapy of Rheumatic Diseases-Practice and Prospects," *Immunol. Today*, 12(6):177-179 (1991); and Trentham, D. E., "Immunotherapy and Other Novel Therapies," *Curr. Opin. Rheumatol.*, 3:369-372 (1991).

Please amend the above-identified application as follows:

In the Specification:

On page 16, line 12, delete "is a graphical representation" and insert therefor -- are graphical representations --;

On page 27, line 28, delete "region" and insert therefor -- regions --.

On page 42, line 20, delete "off" and insert therefor -- of --.

On page 100, lines 10-11, delete "XIV and XV" and insert therefor -- XIII and XIV --; line 23, delete "XIV and XV" and insert therefor -- XIII and XIV --; line 33, delete "XIV and XV" and insert therefor -- XIII and XIV --.

On page 101, lines 4-5, delete "XIV and XV" and insert therefor -- XIII and XIV --; line 19, delete "XIV and XV" and insert therefor -- XIII and XIV --; line 23, delete "XIV and XV" and insert therefor -- XIII and XIV --; line 28, delete "XIV and XV" and insert therefor -- XIII and XIV --.

On page 102, line 8, delete "XIV and XV" and insert therefor -- XIII and XIV --; line 16, delete "XIV and XV" and